

Resource Summary Report

Generated by [dkNET](#) on Aug 2, 2026

CD8 antibody [144B]

RRID:AB_443686

Type: Antibody

Proper Citation

Abcam Cat# ab17147, RRID:AB_443686

Antibody Information

URL: http://antibodyregistry.org/AB_443686

Proper Citation: Abcam Cat# ab17147, RRID:AB_443686

Target Antigen: CD8 antibody [144B]

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: IHC-P, IHC-R, WB; Immunohistochemistry - fixed; Western Blot; Immunohistochemistry

Antibody Name: CD8 antibody [144B]

Description: This monoclonal targets CD8 antibody [144B]

Target Organism: human

Antibody ID: AB_443686

Vendor: Abcam

Catalog Number: ab17147

Record Creation Time: 20250820T024445+0000

Record Last Update: 20250820T142414+0000

Ratings and Alerts

No rating or validation information has been found for CD8 antibody [144B].

No alerts have been found for CD8 antibody [144B].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Peng T, et al. (2025) Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. *Cell stem cell*, 32(4), 652.

Liu Z, et al. (2025) A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. *Cell*, 188(11), 3081.

Xing Y, et al. (2025) Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer. *Developmental cell*.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. *Cancer immunology research*, 12(4), 491.

Zhang J, et al. (2024) Pyroptotic T cell-derived active IL-16 has a driving function in ovarian endometriosis development. *Cell reports. Medicine*, 5(3), 101476.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. *Cell reports. Medicine*, 5(3), 101469.

Yu J, et al. (2024) Progesterone-driven B7-H4 contributes to onco-fetal immune tolerance. *Cell*, 187(17), 4713.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. *Molecular cancer therapeutics*, 23(1), 68.

Zhu R, et al. (2024) ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. *Cell metabolism*.

Li G, et al. (2023) Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. *Cancer cell*, 41(2), 304.

Trinh T, et al. (2023) CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. *iScience*, 26(4), 106443.

Wang Y, et al. (2023) Expression of FOXA1 Is Associated with the Tumor-Infiltrating M2 Macrophage, Cytotoxic T Lymphocyte, and Effect of Chemotherapy in Bladder Cancer. *Urologia internationalis*, 107(1), 58.

Guo D, et al. (2022) Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I?B?. *Cell metabolism*, 34(9), 1312.

Koikawa K, et al. (2021) Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. *Cell*, 184(18), 4753.

Sun Y, et al. (2021) Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. *Cell*, 184(2), 404.

Kaddatz H, et al. (2021) Cuprizone-induced demyelination triggers a CD8-pronounced T cell recruitment. *Glia*, 69(4), 925.

Hornburg M, et al. (2021) Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. *Cancer cell*, 39(7), 928.

Dong L, et al. (2021) The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. *Cancer cell*, 39(7), 945.

Sun C, et al. (2020) THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. *Cancer cell*, 37(2), 216.